芪苈强心胶囊联合瑞舒伐他汀治疗急性心肌梗死的临床研究

目的探讨芪苈强心胶囊联合瑞舒伐他汀钙片治疗急性心肌梗死的临床疗效。方法选取2018年2月—2020年8月洛阳石化医院收治的76例急性心肌梗死患者,根据随机数字表法将所有患者分为对照组和治疗组,每组各38例。对照组口服瑞舒伐他汀钙片,10 mg/次,1次/d。治疗组在对照组的基础上口服芪苈强心胶囊,4粒/次,3次/d。两组患者连续治疗4周。观察两组的临床疗效,比较治疗前后心功能指标和血清因子水平。结果治疗后,治疗组的总有效率为94.74%,对照组的总有效率为78.95%,两组比较差异有统计学意义(P<0.05)。治疗后,两组的左心室射血分数(LVEF)、内皮依赖性血管舒张功能(FMD)明显升高,左心室收缩末期内径(LVESD)明显降低(P<0.05);且治疗后治疗组的LVEF、FMD高于对照组,LVESD低于对照组,差异有统计学意义(P<0.05)。治疗后,两组的超敏C反应蛋白(hs-CRP)、肿瘤坏死因子-α(TNF-α)、脑钠肽(BNP)、α-羟丁酸脱氢酶(α-HBD)水平显著降低(P<0.05);且治疗后治疗组的hs-CRP、TNF-α、BNP、α-HBD水平低于对照组,差异有统计学意义(P<0.05)。结论芪苈强心胶囊联合瑞舒伐他汀钙片可提高急性心肌梗死的临床疗效,改善心功能,减轻炎症反应,安全性良好。

Clinical study of Qili Qiangxin Capsules combined with rosuvastatin in treatment of acute myocardial infarction

Objective To investigate the clinical effect of Qili Qiangxin Capsules combined with Rosuvastatin Calcium Tablets in treatment of acute myocardial infarction. Methods Patients(76 cases) with acute myocardial infarction in Luoyang Petrochemical Hospital from February 2018 to August 20120 were randomly divided into control and treatment groups, and each group had 38 cases. Patients in the control group were po administered with Rosuvastatin Calcium Tablets, 10 mg/time, once daily. Patients in the treatment group were po administered with Qili Qiangxin Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and cardiac function index and serum factor levels in two groups were compared. Results After treatment, the total effective rate of the treatment group was 94.74%, and that of the control group was 78.95%, and the difference between two groups was statistically significant(P < 0.05). After treatment, LVEF and FMD of two groups were significantly increased, but LVESD of two groups was significantly decreased(P < 0.05). After treatment, LVEF and FMD of the treatment group were higher than those of the control group, but LVESD of the treatment group was lower than that of the control group, and the difference was statistically significant(P < 0.05). After treatment, the levels of hs-CRP, TNF-α, BNP, and α-HBD in two groups were significantly decreased(P < 0.05). And after treatment, the levels of hs-CRP, TNF-α, BNP, and α-HBD in the treatment group were lower than those in the control group, the difference was statistically significant(P < 0.05). Conclusion Qili Qiangxin Capsules combined with Rosuvastatin Calcium Tablets can improve the clinical efficacy of acute myocardial infarction, improve cardiac function, reduce inflammatory reaction, with good safety.